Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Harnessing native fat-residing stem cells for bone regeneration

  • Post author:
  • Post published:June 15, 2026
  • Post category:

Like most tissues of the body, bone possesses a natural regenerative system aimed at restoring cells and tissues lost to natural cell aging, disease or injury. These natural regenerative systems…

Continue ReadingHarnessing native fat-residing stem cells for bone regeneration

Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis

  • Post author:
  • Post published:June 15, 2026
  • Post category:

The ability to direct the differentiation of resident mesenchymal stem cells (MSCs) towards the cartilage lineage offers considerable promise for the regeneration of articular cartilage after traumatic joint injury or…

Continue ReadingCartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis

Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy

  • Post author:
  • Post published:June 15, 2026
  • Post category:

Cancer is the leading cause of death for individuals under 85. Relapse and metastatic disease are the leading causes of cancer related mortality. Anti-apoptotic BCL2 family member overexpression has been…

Continue ReadingPreclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy

A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants

  • Post author:
  • Post published:June 14, 2026
  • Post category:

This trial proposes to replace SCID patients' dysfunctional immune cells with healthy ones using a safer form of bone marrow transplant (BMT). Current BMT procedures must use toxic chemotherapy to…

Continue ReadingA monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants

Retinal progenitor cells for treatment of retinitis pigmentosa

  • Post author:
  • Post published:June 14, 2026
  • Post category:

Retinitis pigmentosa (RP) is a severe form of blindness that runs in families with an incidence of 1:4000. A team at UC Irvine, is using cells called retinal progenitor cells…

Continue ReadingRetinal progenitor cells for treatment of retinitis pigmentosa

A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events

  • Post author:
  • Post published:June 14, 2026
  • Post category:

Continue ReadingA First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent Cardiovascular Events

Gene Therapy for Alpha-1 Anti-Trypsin Deficiency

  • Post author:
  • Post published:June 14, 2026
  • Post category:

Continue ReadingGene Therapy for Alpha-1 Anti-Trypsin Deficiency

Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

  • Post author:
  • Post published:June 14, 2026
  • Post category:

Continue ReadingLate-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies

Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9

  • Post author:
  • Post published:June 14, 2026
  • Post category:

Continue ReadingAdvancement of a myotropic, liver-detargeting therapy for LGMD2i/R9

A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia

  • Post author:
  • Post published:June 14, 2026
  • Post category:

Continue ReadingA first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us